Jacqueline S Stevens, Christopher A Barker, Richard L Bakst, Carol Bradford, David R Carr, Bhisham Chera, Michelle Chen, Sunandana Chandra, Addison Demer, Heidi Donnelly, Bently Doonan, Thomas J Galloway, Jessica Geiger, Anokhi Jambusaria, Nikhil I Khushalani, Shlomo Koyfman, Justin J Leitenberger, Elizabeth Lilley, John Nicholas Lukens, Danielle Margalit, Theresa Medina, Devarati Mitra, Vinayak Muralidhar, Jonathan Paly, Itai Pashtan, Vishal Patel, Rosh Sethi, Monica Shukla, Ann W Silk, Divya Srivastava, Paul Swiecicki, Matthew Witek, Ashley Wysong, Sue Yom, Jonathan D Schoenfeld, Emily S Ruiz
{"title":"US-based Delphi Consensus Study on Adjuvant Radiation Therapy (ART) in Node-Negative Cutaneous Squamous Cell Carcinoma (CSCC).","authors":"Jacqueline S Stevens, Christopher A Barker, Richard L Bakst, Carol Bradford, David R Carr, Bhisham Chera, Michelle Chen, Sunandana Chandra, Addison Demer, Heidi Donnelly, Bently Doonan, Thomas J Galloway, Jessica Geiger, Anokhi Jambusaria, Nikhil I Khushalani, Shlomo Koyfman, Justin J Leitenberger, Elizabeth Lilley, John Nicholas Lukens, Danielle Margalit, Theresa Medina, Devarati Mitra, Vinayak Muralidhar, Jonathan Paly, Itai Pashtan, Vishal Patel, Rosh Sethi, Monica Shukla, Ann W Silk, Divya Srivastava, Paul Swiecicki, Matthew Witek, Ashley Wysong, Sue Yom, Jonathan D Schoenfeld, Emily S Ruiz","doi":"10.1016/j.ijrobp.2026.09.022","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>There is a paucity of high-level evidence for adjuvant radiation therapy (ART) in cutaneous squamous cell carcinoma (CSCC) creating practice variations. This study provides expert consensus recommendations on patient and tumor selection, timing, duration, dosage, and additional considerations for ART in node-negative CSCC.</p><p><strong>Methods: </strong>The Delphi panel included 35 experts in radiation oncology (15), dermatology/Mohs micrographic surgery (9), medical oncology (7), head and neck surgery (3), and surgical oncology (1). Consensus was defined as ≥80% concordance; near-consensus 70-79% concordance.</p><p><strong>Results: </strong>Consensus was reached to recommend ART when further surgery is not possible, but the tumor has positive gross or histologic/microscopic margins (35/35, 100%). Key consensus or near-consensus recommendations for recommending ART to the tumor bed following negative-margin surgery include: 5-year cumulative incidence of local recurrence (29/35, 83%) or nodal metastasis (27/35, 77%) ≥ 20%; gross cortical bone/marrow invasion (32/35, 91%); skull base invasion (32/35, 91%); 4 risk factors (RF) (35/35, 100%); 3 RF (30-33/35, 86-94%); PNI ≥ 0.1 mm and one other RF (30/35, 86%); and clinical nerve invasion (31/35, 89%). Immune status influenced ART decision-making (30/35, 86%) with 77% (27/35) more likely to recommend ART for immunosuppressed patients. Consensus was reached to omit ART for pathologic complete response following neoadjuvant immunotherapy (34/35, 97%). Among radiation oncologists, 100% (15/15) agreed the optimal window for ART to the tumor bed is 4-8 weeks and that hypofractionated regimens can be appropriate (12/15, 80%). Consensus was reached for prescription doses of 60-66 Gy in 2 Gy/fx (15/15, 100%) or 50-55 Gy in 2.5 Gy/fx (13/15, 87%), and that superficial radiation and brachytherapy are inappropriate ART modalities for node-negative high-stage CSCC (14/15, 93%). There was no consensus on elective nodal basin irradiation.</p><p><strong>Conclusions: </strong>This Delphi study provides an expert consensus-based framework to standardize ART for node-negative high-stage CSCC following surgery, informing future guidelines and utilization.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":7.4000,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2026.09.022","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: There is a paucity of high-level evidence for adjuvant radiation therapy (ART) in cutaneous squamous cell carcinoma (CSCC) creating practice variations. This study provides expert consensus recommendations on patient and tumor selection, timing, duration, dosage, and additional considerations for ART in node-negative CSCC.
Methods: The Delphi panel included 35 experts in radiation oncology (15), dermatology/Mohs micrographic surgery (9), medical oncology (7), head and neck surgery (3), and surgical oncology (1). Consensus was defined as ≥80% concordance; near-consensus 70-79% concordance.
Results: Consensus was reached to recommend ART when further surgery is not possible, but the tumor has positive gross or histologic/microscopic margins (35/35, 100%). Key consensus or near-consensus recommendations for recommending ART to the tumor bed following negative-margin surgery include: 5-year cumulative incidence of local recurrence (29/35, 83%) or nodal metastasis (27/35, 77%) ≥ 20%; gross cortical bone/marrow invasion (32/35, 91%); skull base invasion (32/35, 91%); 4 risk factors (RF) (35/35, 100%); 3 RF (30-33/35, 86-94%); PNI ≥ 0.1 mm and one other RF (30/35, 86%); and clinical nerve invasion (31/35, 89%). Immune status influenced ART decision-making (30/35, 86%) with 77% (27/35) more likely to recommend ART for immunosuppressed patients. Consensus was reached to omit ART for pathologic complete response following neoadjuvant immunotherapy (34/35, 97%). Among radiation oncologists, 100% (15/15) agreed the optimal window for ART to the tumor bed is 4-8 weeks and that hypofractionated regimens can be appropriate (12/15, 80%). Consensus was reached for prescription doses of 60-66 Gy in 2 Gy/fx (15/15, 100%) or 50-55 Gy in 2.5 Gy/fx (13/15, 87%), and that superficial radiation and brachytherapy are inappropriate ART modalities for node-negative high-stage CSCC (14/15, 93%). There was no consensus on elective nodal basin irradiation.
Conclusions: This Delphi study provides an expert consensus-based framework to standardize ART for node-negative high-stage CSCC following surgery, informing future guidelines and utilization.
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.